Ally Bridge Group (Ny) LLC Arvinas, Inc. Transaction History

Ally Bridge Group (Ny) LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$36.01 - $74.24 $5.4 Million - $11.1 Million	-150,000 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$60.27 - $81.57 $4.82 Million - $6.53 Million	-80,000 Reduced 34.78%	150,000 $10.1 Million
Q4 2021 Feb 14, 2022	BUY	$65.85 - $96.21 $1.32 Million - $1.92 Million	20,000 Added 9.52%	230,000 $18.9 Million
Q3 2021 Nov 15, 2021	SELL	$73.2 - $107.87 $2.2 Million - $3.24 Million	-30,000 Reduced 12.5%	210,000 $17.3 Million
Q2 2021 Aug 16, 2021	BUY	$60.45 - $84.26 $8.21 Million - $11.4 Million	135,747 Added 130.21%	240,000 $18.5 Million
Q1 2021 May 17, 2021	BUY	$58.19 - $91.37 $247,482 - $388,596	4,253 Added 4.25%	104,253 $6.89 Million
Q4 2020 Feb 16, 2021	BUY	$20.19 - $84.93 $2.02 Million - $8.49 Million	100,000 New	100,000 $8.49 Million

229

68.4M

226K

285K

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $997M
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

Get notified when there are updates to the investment portfolio of Ally Bridge Group (Ny) LLC, based on Form 13F filings with the SEC.

Stay updated on Ally Bridge Group (Ny) LLC with notifications on news.